Beatriz Prieto Antolín, Eduardo Gutiérrez-Abejón, Susana Alberola López, Jesús María Andrés de Llano
{"title":"[Trend in medicines use for attention deficit hyperactivity disorder in children and adolescents (2010-2019).]","authors":"Beatriz Prieto Antolín, Eduardo Gutiérrez-Abejón, Susana Alberola López, Jesús María Andrés de Llano","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Attention deficit hyperactivity disorder (ADHD) is a common childhood neurodevelopmental disorder characterised primarily by three core symptoms: inattention, hyperactivity and impulsivity. It is one of the most commonly diagnosed childhood psychiatric disorders, with a worldwide prevalence of between 3% and 5%, and between 6% and 7% in the Spanish population. The aim of the study is to analyse the trend in the consumption of drugs used for the treatment of ADHD between 2010-2019 in Castilla y León.</p><p><strong>Methods: </strong>Epidemiological registry study of all dispensing in pharmacies in Castilla y León between 2010 and 2019 to patients under 19 years of age, of active substance N06BA04 (methylphenidate), N06BA09 (atomoxetine), N06BA12 (lisdexamfetamine), N06BA07 (modafinil) and C02AC02 (guanfacine). Data on drug use were obtained from the information system for the pharmaceutical provision of Castilla y León, CONCYLIA. Frequencies in absolute values and the corresponding percentages were calculated. Student's t-test was used to estimate differences between continuous variables and Pearson's Chi-square test for categorical variables, while the trend in consumption was analysed using the Cochran-Armitage test.</p><p><strong>Results: </strong>ADHD medication was dispensed annually to 1.77% of the population, with consumption being more than three times higher in boys than in girls (2.69% vs 0.81%; p=0.001). The age group with the highest peak use was 10-14 years with 3.42%. Methylphenidate was the drug used by the highest percentage of the population (2.44%) followed by lisdexamfetamine (0.37%).</p><p><strong>Conclusions: </strong>Approximately 2 out of every 100 people aged 0-19 years were treated with some ADHD medication, mainly methylphenidate, in Castilla y León between 2010 and 2019.</p>","PeriodicalId":47152,"journal":{"name":"Revista Espanola De Salud Publica","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2022-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola De Salud Publica","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Attention deficit hyperactivity disorder (ADHD) is a common childhood neurodevelopmental disorder characterised primarily by three core symptoms: inattention, hyperactivity and impulsivity. It is one of the most commonly diagnosed childhood psychiatric disorders, with a worldwide prevalence of between 3% and 5%, and between 6% and 7% in the Spanish population. The aim of the study is to analyse the trend in the consumption of drugs used for the treatment of ADHD between 2010-2019 in Castilla y León.
Methods: Epidemiological registry study of all dispensing in pharmacies in Castilla y León between 2010 and 2019 to patients under 19 years of age, of active substance N06BA04 (methylphenidate), N06BA09 (atomoxetine), N06BA12 (lisdexamfetamine), N06BA07 (modafinil) and C02AC02 (guanfacine). Data on drug use were obtained from the information system for the pharmaceutical provision of Castilla y León, CONCYLIA. Frequencies in absolute values and the corresponding percentages were calculated. Student's t-test was used to estimate differences between continuous variables and Pearson's Chi-square test for categorical variables, while the trend in consumption was analysed using the Cochran-Armitage test.
Results: ADHD medication was dispensed annually to 1.77% of the population, with consumption being more than three times higher in boys than in girls (2.69% vs 0.81%; p=0.001). The age group with the highest peak use was 10-14 years with 3.42%. Methylphenidate was the drug used by the highest percentage of the population (2.44%) followed by lisdexamfetamine (0.37%).
Conclusions: Approximately 2 out of every 100 people aged 0-19 years were treated with some ADHD medication, mainly methylphenidate, in Castilla y León between 2010 and 2019.
目的:注意缺陷多动障碍(ADHD)是一种常见的儿童神经发育障碍,主要表现为三个核心症状:注意力不集中、多动和冲动。它是最常见的儿童精神疾病之一,全球患病率在3%至5%之间,在西班牙人口中患病率在6%至7%之间。该研究的目的是分析2010-2019年Castilla y León用于治疗ADHD的药物消费趋势。方法:对2010 - 2019年Castilla y León所有药店配售的19岁以下患者的活性物质N06BA04(哌甲酯)、N06BA09(托莫西汀)、N06BA12(利地胺非他明)、N06BA07(莫达非尼)和C02AC02(胍法辛)进行流行病学登记研究。关于药物使用的数据是从CONCYLIA Castilla y León提供药品的信息系统获得的。计算频率绝对值和相应的百分比。使用学生t检验估计连续变量之间的差异,使用Pearson卡方检验估计分类变量之间的差异,使用Cochran-Armitage检验分析消费趋势。结果:每年有1.77%的人使用ADHD药物,其中男孩的使用量是女孩的3倍多(2.69% vs 0.81%;p = 0.001)。10 ~ 14岁是使用高峰年龄段,占3.42%。使用哌甲酯的比例最高(2.44%),其次是利地塞米安(0.37%)。结论:在2010年至2019年期间,Castilla y León每100名0-19岁的人中约有2人接受了一些ADHD药物治疗,主要是哌甲酯。